Gastroenterology and hepatology from bed to bench · 2025
Analysis of complete and incomplete response to neoadjuvant therapy in rectum cancer patients.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
TajikRostami Fatemeh, Tavirani Majid Rezaei, Ataei Elnaz, Rezaei-Tavirani Mostafa, Mohaghegh-Shalmani Hamid, Norouzinia Mohsen
Аннотация
AIM: Bioinformatic analysis of the differentially expressed genes (DEGs) of the two groups of patients is the main aim of this project.
BACKGROUND: Neoadjuvant therapy is a method to treatment disease before local surgery. This method has been administrated to treatment rectum cancer; complete and incomplete responses are observed in patients.
METHODS: The DEGs of gene expression profiles of patients with complete and incomplete response to treatment with neoadjuvant therapy were explored from recorded data in Gene Expression Omnibus (GEO) database and evaluated via protein-protein interaction (PPI) analysis and gene ontology assessment.
RESULTS: Among 606 significant DEGs, EGFR, JUN, CDK4, IGF1, and APP were pointed out as the key genes that are involved in response model to neoadjuvant therapy while "GnRH signaling pathway" and "regulation of multicellular organism growth" were introduced as the major involved groups of biological terms.
CONCLUSION: It can be concluded that, there is genetic variation between rectum cancer patients and efficacy enhancement of treatment need considering precision medicine perspective.
BACKGROUND: Neoadjuvant therapy is a method to treatment disease before local surgery. This method has been administrated to treatment rectum cancer; complete and incomplete responses are observed in patients.
METHODS: The DEGs of gene expression profiles of patients with complete and incomplete response to treatment with neoadjuvant therapy were explored from recorded data in Gene Expression Omnibus (GEO) database and evaluated via protein-protein interaction (PPI) analysis and gene ontology assessment.
RESULTS: Among 606 significant DEGs, EGFR, JUN, CDK4, IGF1, and APP were pointed out as the key genes that are involved in response model to neoadjuvant therapy while "GnRH signaling pathway" and "regulation of multicellular organism growth" were introduced as the major involved groups of biological terms.
CONCLUSION: It can be concluded that, there is genetic variation between rectum cancer patients and efficacy enhancement of treatment need considering precision medicine perspective.